These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28891712)

  • 1. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
    De Pas T; Pala L; Catania C; Conforti F
    Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
    Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
    Santarpia M; Daffinà MG; D'Aveni A; Marabello G; Liguori A; Giovannetti E; Karachaliou N; Gonzalez Cao M; Rosell R; Altavilla G
    Drug Des Devel Ther; 2017; 11():2047-2063. PubMed ID: 28740365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].
    Giroux Leprieur E; Fallet V; Wislez M
    Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
    Zhao X; Feng Z; Wang G; Pang H; Wang M
    Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
    Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
    J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.